Amgen To Pay Hospital $186M Over Royalties

Law360, New York (June 6, 2006, 12:00 AM EDT) -- Amgen Inc. has agreed to pay Massachusetts General Hospital $186 million to resolve a royalty spat over a lucrative drug for arthritis treatment that dragged on for more than a year.

Amgen, based in Thousand Oaks, Calif., has agreed to end future North American royalty payments for Enbrel, which is used to treat rheumatoid arthritis and psoriasis. The hospital will continue to receive royalties from Enbrel sales outside North America.

The drug’s combined royalty brought in nearly 75% of Massachusetts General’s $90 million in licensing fees...
To view the full article, register now.